Clinical Trial Results Educational Lecture Series
Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting 2007
This program provides expert coverage of late breaking trial news and balanced clinical information covered on the behalf of ClinicalTrialResults.org. A variety of current topics in cardiology and disease management were captured during the October 2007 TCT Annual Meeting held in Washington, DC.
Presentation 1  view presentation
ARMYDA-4:
Germano Di Sciascio, MD, FACC, FESC discusses the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty (ARMYDA-4) study, which investigated the influence on PCI outcome of additional 600 mg clopidogrel load in patients on chronic therapy. Dr. Germano Di Sciascio is the chairman for the study.
Presentation 2 view presentation
ARMYDA-5
Germano Di Sciascio, MD, FACC, FESC discusses the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty (ARMYDA-5) study, which investigated the influence on PCI outcome of in-lab 600 mg clopidogrel loading versus a 6 hour pre-PCI treatment. Dr. Germano Di Sciascio is the chairman for the study.
Presentation 3 view presentation
The Benefit of Statin Therapy Before and After Coronary Revascularization
C. Michael Gibson, MS, MD, the founder of CTR.org, discusses data from the ARMYDA-ACS trial; the goal of ARMYDA-ACS was to evaluate the effect of atorvastatin compared with placebo among patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). In addition, Dr. Gibson discusses statin use with myocardial perfusion.
Presentation 4 view presentation
Clopidogrel Response Variability and Resistance
Paul Gurbel, MD discusses the platelet activation pathway, clopidogrel action, and the nature of clopidogrel resistance and variation in therapeutic response.
Presentation 5 view presentation
TRA-PCI Update on the New Antiplatelet Agents: PAR-1 Inhibitors
David J. Moliterno, MD, MPH provides an update on the TRA-PCI trial, which studies the new antiplatelet agent SCH 530348. SCH 530348 is an oral, potent, selective thrombin receptor antagonist (TRA) being developed for the prevention and treatment of atherothrombosis which is an antagonist of the PAR-1 receptor.
Presentation 6 view presentation
Evidence-Based Medicine Therapies in ACS: From Principles to Practice
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI discusses changes taking place in the Healthcare system: quality of care, costs, guidelines, performance measurements, and the CRUSADE and ACTION initiatives.
Presentation 7 view presentation
CRUSADE/ACTION Update
Eric D. Peterson, MD, MPH, FAHA, FACC presents and update on the CRUSADE/ACTION national CQI.
Presentation 8 view presentation
TAXUS ATLAS Small Vessel and Long Lesion
Mark A. Turco, MD, FACC, FSCAI presents results from the TAXUS ATLAS trial which studied improvements in stent technologies and their impact on stent performance.
|
